Swedish private-equity firm EQT has agreed to acquire molecular diagnostics company Qiagen for approximately €9.6 billion ($10.78 billion), bringing an end to years of takeover speculation surrounding the Dutch healthcare technology group and highlighting growing investor interest in businesses serving the molecular testing market.
EQT is offering €46.50 per share, representing an 8.6% premium to Qiagen’s last closing price, the companies said on Wednesday. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are also participating in the offer, bringing additional institutional capital into the transaction.
The deal values Qiagen at approximately $12.1 billion, including about $1.1 billion in net debt, and is expected to close in mid-2027. EQT said it had secured the equity and debt financing required to fund the acquisition.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Qiagen’s board has approved the offer, with supervisory board chairman Stephen Rusckowski describing a move into private ownership as the “best path forward for Qiagen, its shareholders and other stakeholders.”
The acquisition comes as demand for molecular testing technologies continues to attract private-equity investment. Qiagen supplies products and services used to analyze genetic material in research and clinical laboratories, placing it at the intersection of healthcare diagnostics, life sciences research and biotechnology.
Qiagen has attracted acquisition interest for several years, with its takeover history shaped by changes in leadership, the COVID-19 pandemic and shifting investor expectations.
The company became a takeover target after former chief executive Peer Schatz announced his departure in October 2019. In 2020, US laboratory equipment maker Thermo Fisher Scientific agreed to acquire Qiagen in a transaction valued at approximately $11.5 billion.
That deal ultimately collapsed after Thermo Fisher failed to secure sufficient shareholder support, leaving Qiagen independent and exposing the difficulty of agreeing on a valuation acceptable to both buyers and investors.
The pandemic subsequently transformed Qiagen’s financial performance. Demand for its coronavirus testing products surged as governments, healthcare providers and laboratories expanded testing capacity, boosting the company’s business and share price.
The exceptional demand also complicated the valuation debate. Some investors viewed the earlier Thermo Fisher offer as too low in light of the company’s pandemic-era performance and the opportunities they saw in its diagnostics business.
As demand for COVID-19 testing later changed, investors had to reassess how much of Qiagen’s growth could be sustained beyond the pandemic. The resulting uncertainty contributed to pressure on the stock, although renewed takeover speculation helped support its recovery.
Qiagen shares had fallen to more than six-year lows in May before reports of interest from private-equity firms, including EQT, helped revive the takeover narrative. The stock has gained approximately 10% so far this year, while its US-listed shares rose 0.7% in extended trading following Wednesday’s announcement.
The agreed price offers shareholders a premium to the last closing level, but the relatively modest 8.6% premium also illustrates the balance between securing shareholder approval and maintaining acquisition discipline in a business whose prospects have been shaped by unusually volatile demand.
Private Equity Targets Specialized Healthcare Technology
The acquisition reflects private-equity firms’ continued interest in healthcare businesses with established technologies, specialized customer relationships, and exposure to structural demand for diagnostics and life sciences research.
Molecular testing enables laboratories to analyze genetic material for applications ranging from disease detection to scientific research. Demand for these technologies is influenced by developments in clinical diagnostics, pharmaceutical research, and the broader use of molecular analysis in healthcare.
Such businesses can offer investors exposure to specialized markets without relying entirely on the commercial success of a single drug or therapeutic product. However, their performance still depends on research spending, healthcare budgets, product development, and the ability to maintain demand as testing requirements change.
Qiagen’s experience during the pandemic demonstrated both the opportunities and the risks associated with the sector. A sudden increase in testing demand can lift sales and profitability, but revenue generated during an exceptional public-health event may not be sustained once conditions normalize.
That history is likely to remain relevant as the company enters a new ownership structure. The long-term investment case will rely on its ability to build sustainable demand across its broader portfolio rather than relying on temporary surges in particular testing categories.
EQT’s participation alongside investors linked to Abu Dhabi and Canada’s pension system also shows how large institutional pools of capital can be combined to finance acquisitions in the healthcare technology market. The transaction’s financing structure gives the buyers the resources to proceed, although the expected mid-2027 closing date leaves the deal subject to the remaining completion requirements.
Alongside the takeover announcement, Qiagen said it was suspending its full-year 2026 outlook pending completion of the transaction.
The company reported preliminary third-quarter net sales of $548 million and adjusted diluted earnings per share of $0.65. The figures provide an indication of its recent performance, but the suspension of guidance limits investors’ ability to assess the company’s full-year trajectory using management’s previous expectations.
The decision also places greater emphasis on the acquisition process as shareholders and other stakeholders assess the proposed transaction. Until the deal closes, Qiagen will continue operating as a standalone business while working through the requirements associated with the change in ownership.
The expected timetable means the acquisition will not immediately resolve questions about the company’s longer-term growth or the durability of demand across its product portfolio. Instead, it establishes a new ownership framework under which those challenges will be addressed.